Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year randomized placebo-controlled phase 3 study of inhaled mometasone furoate/formoterol in moderate to severe COPD
2006-002308-32Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mometasone and formoterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in FEV1 AUC0-12 hours at week 13 endpoint. Started Oct 2006; status: completed.
02
Drugs
mometasoneformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-002308-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002308-32.